Oncology Meeting Resources

In this section, you can find all available abstracts, presentations and webcasts on OncologyPRO.

Here below, you can search across all meeting resources by session title, presentation title, presenter or keyword. Results can then be refined by topic, event and publication date.

The use of these presentations is for personal educational purposes only.
ESMO thanks the authors for their generosity.




Format available

https://oncologypro.esmo.org/Meeting-Resour...ess/Invited-Discussant-172PD-173PD-and-174PD

Date: 18 Dec 2016
Presenter: Tae Won Kim
Resources: Presentation, Webcast
Topics: Cytotoxic agents,, Colon and Rectal Cancer,, Translational Research

https://oncologypro.esmo.org/Meeting-Resour...C-with-a-PD-L1-tumor-proportion-score-TPS-50

BackgroundPlatinum-based doublet chemo is the standard first-line therapy for advanced NSCLC without a treatable oncogenic aberration. Pembro (anti–PD-1) is approved in the US and EU for previously...

Date: 18 Dec 2016
Presenter: Martin Reck
Resources: Abstract
Topics: Cytotoxic agents,, Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...-naive-and-neoadjuvant-chemotherapy-patients

BackgroundTo investigate the role of color Doppler parameters in carcinoma breast as non invasive prognostic marker.MethodsA total of 92 patients o carcinoma of breast who are all candidate for surgery...

Date: 18 Dec 2016
Presenter: H B Govardhan
Resources: Abstract
Topics: Cytotoxic agents,, Staging procedures (clinical staging)

https://oncologypro.esmo.org/Meeting-Resour...erative-adjuvant-treatment-for-breast-cancer

BackgroundNo study has investigated patients’ preference for orally disintegrating tablets (OD) or granules (GN) in patients with breast cancer. In a phase III randomized study of adjuvant one-year...

Date: 18 Dec 2016
Presenter: Ippei Fukada
Resources: Abstract
Topics: Cytotoxic agents,,

https://oncologypro.esmo.org/Meeting-Resour...motherapy-for-locally-advanced-breast-cancer

BackgroundNeoadjuvant chemotherapy (CTX) is a standard therapy in locally advanced breast cancer. Arglabin is a sesquiterpene gamma-lactone isolated from Artemisia glabella, a species of wormwood endemic...

Date: 18 Dec 2016
Presenter: Yuriy Fomenko
Resources: Abstract
Topics: Cytotoxic agents,

https://oncologypro.esmo.org/Meeting-Resour...patients-with-locally-advanced-breast-cancer

BackgroundSentinel lymph node provides reliable node staging information for clinically node negative and chemo naive breast cancer patients while its role after neoadjuvant chemotherapy remains unclear...

Date: 18 Dec 2016
Presenter: Amer Chikh Youssef
Resources: Abstract
Topics: Cytotoxic agents,, Pathology/Molecular Biology, Surgical oncology

https://oncologypro.esmo.org/Meeting-Resour...-with-clinically-node-positive-breast-cancer

BackgroundNeoadjuvant chemotherapy (NAC) is the standard treatment for patients with clinically node-positive breast cancer. An axillary pathologic complete response (pCR) is associated with excellent...

Date: 18 Dec 2016
Presenter: Hyung Suk Kim
Resources: Abstract
Topics: Cytotoxic agents,, Surgical oncology

https://oncologypro.esmo.org/Meeting-Resour...-with-HER2-negative-metastatic-breast-cancer

BackgroundEribulin (ERI) is one of the standards of care in metastatic breast cancer (MBC) after anthracycline and taxane. In 301 trial, overall survival of ERI was comparable to that of capecitabine ...

Date: 18 Dec 2016
Presenter: Natsuko Tsushita
Resources: Abstract
Topics: Cytotoxic agents,

https://oncologypro.esmo.org/Meeting-Resour...t-cancer-Single-centre-experience-from-India

BackgroundPatients with advanced breast cancer are usually resistant to anthracyclines and taxanes. Treatment failure is observed in majority of metastatic breast cancer patients and 5 year survival rate is only 27%.

Date: 18 Dec 2016
Presenter: Ajay Sharma
Resources: Abstract
Topics: Cytotoxic agents,

https://oncologypro.esmo.org/Meeting-Resour...anese-multicenter-phase-2-study-SBP-04-study

BackgroundThe efficacy of eribulin for HER2 negative metastatic breast cancer (MBC) was confirmed by EMBRACE trial. However, there is no definitive Asian evidence about efficacy and safety of eribulin...

Date: 18 Dec 2016
Presenter: Tadahiko Shien
Resources: Abstract
Topics: Cytotoxic agents,,